Introduction {#sec1-1}
============

Periungual warts a common skin disease and can interfere with nails development, mainly in immunosuppressed patients \[[@ref1]\], \[[@ref2]\].

Tissue destruction therapy is painful, and the recurrence is frequent. Imiquimod is a topical immunosuppressive agent, which stimulates the production of inflammatory cytokines that activate and maintain cell-mediated immune response \[[@ref3]\].

This study aimed to evaluate the efficacy of imiquimod 5%, once daily for 5 consecutive days per week, in periungual wart treatment in 40 Vietnamese patients, including 19 females (aged 20.4 ± 13.8) and 21 males (aged 27.3 ± 13.5) patients.

Material and Methods {#sec1-2}
====================

A group of 40 patients were recruited to apply imiquimod 5 % cream once daily for 5 consecutive days per week in 8 weeks. They were classified into 3 levels: Mild (the total lesion area ≤ 25 mm^2^), moderate (25 mm^2^ \<total lesion area ≤ 50 mm^2^), severe (total lesion area \> 50 mm^2^).

The outcome was evaluated at the 4th and the 8th week.

The result was graded as excellent (complete clearance), good (≥ 50% clearance) and poor (\< 50% clearance).

Results {#sec1-3}
=======

The warts condition before the treatment was mild in 21 patients (52.5%) (the total lesion area ≤ 25 mm^2^), moderate in 8 patients (20.0%) (25 mm^2^ \<total lesion area ≤ 50 mm^2^) and severe in 11 patients (27.5%) (total lesion area \> 50 mm^2^). The duration of disease was 13.5 ± 15.0 months.

The total area of warts got decreased significantly from 36.7mm^2^ at week 0 to 16.8 mm^2^ at the 4^th^ week and 8.8 mm^2^ at the 8^th^ week (p \< 0.05) as shown in [Figure 1](#F1){ref-type="fig"}. The excellent outcome at the 8^th^ week was higher than that at the week 4^th^ significantly (72.5% vs 22.5%, p = 0.04). The complete clearing rate at the 8^th^ week was significantly higher than that at the 4^th^ week due to the slow effect of imiquimod in stimulating immune cells.

![Wart area (in mm^2^) change by the time](OAMJMS-7-214-g001){#F1}

![Periungual warts before (A) and after (B) treatment with imiquimod 5 % cream](OAMJMS-7-214-g002){#F2}

An excellent outcome was seen in 68.2% of people who had got treated by other modalities before applying imiquimod and 77.8% of naïve patients, the difference was not significant (p = 0.37, Fisher exact test) ([Table 1](#T1){ref-type="table"}).

###### 

Treatment outcomes and related factors

  Outcomes    N    Wart duration(m ± SD)   P      Wart severity at the beginning   P      Treatment before imiquimod   P                                     
  ----------- ---- ----------------------- ------ -------------------------------- ------ ---------------------------- ------ ------ ---- ------ ---- ------ --------------------------------------
  Excellent   29   10.2 ± 14.1             0.02   5                                45.5   24                           82.8   0.03   15   68.2   14   77.8   0.37[\*](#t1f1){ref-type="table-fn"}
  Good/poor   11   22.3 ± 14.3             6      54.5                             5      17.2                         7      31.8   4    22.2               

Fisher's exact test.

No systemic side effects have been reported. Local side effects had been seen in 37.5% patients, but 73.33% of the side effect was mild.

After 6 months of follow-up, there was only one relapse case (3.5%) after 3 months.

Discussion {#sec1-4}
==========

Excellent results in a group of patients suffering mild/moderate wart were higher than that of the group having severe wart (82.8% vs 45.5%, p = 0.03). So longer the duration of disease was, the less effective the treatment modality was \[[@ref4]\], \[[@ref5]\], \[[@ref6]\].

There was only one relapse case after 3 months. It could be explained by the ability of imiquimod cream that can start and maintain HPV specific cell-mediated immunity \[[@ref7]\], \[[@ref8]\], \[[@ref9]\], \[[@ref10]\].

In conclusions, Imiquimod 5% cream is safe and effective drug in the treatment of periungual warts. Early treatment leads to better results.
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